UCB News & Events

Wafra announced that investment funds advised by Wafra have entered into a definitive agreement to acquire Navitas Credit Corp. from United Community Bank, a wholly-owned subsidiary of United Community Banks, for approximately $1.9B in cash. Navitas will continue to be led by its current management team following the closing of the transaction. The transaction is expected to be completed in the third quarter of 2026 and is subject to customary closing conditions. Bank of America and Wells Fargo are providing acquisition financing, as well as $1B of additional financing capacity to support Navitas' continued growth.

S&P futures are pointing higher to end the week, building on Thursday's rally. The market is being driven by a combination of easing geopolitical fears, a sharp decline in oil prices, and continued enthusiasm around AI-related stocks and the highly anticipated SpaceX IPO.President Trump indicated that an Iran peace agreement could be signed as soon as this weekend, causing crude oil to tumble below $90 per barrel. Lower oil prices are helping calm inflation fears after this week's hotter-than-expected CPI and PPI reports. Markets are betting that if energy prices continue falling, some of the inflation pressure could ease in coming months.Thursday saw a rebound in semiconductor names after two difficult sessions. Investors are also watching the debut of SpaceX, whose massive IPO is expected to be one of the largest market events of the year and could further fuel enthusiasm for AI, aerospace and growth stocks.In pre-market trading, S&P 500 futures rose 0.20%, Nasdaq futures were flat and Dow futures rose 0.44%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -United Community Banksup 2% after executing a definitive agreement to sell its equipment finance business for $1.9B in cashUP AHEAD OF SPACEX IPO:EchoStarup 5%Rocket Labup 3%AST SpaceMobileup 1%DOWN AFTER EARNINGS -Adobedown 8%RHdown 2%51Talk Online Educationdown 7%Laser Photonicsdown 7%Lennardown 1%LOWER -Jazz Pharmaceuticalsdown 1% after announcing its LAGOON trial did not meet its primary endpoint of overall survival evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecanSummit Hotel Propertiesdown 1% after reporting that CFO William Conkling will depart the company effective June 15 for personal reasonsShelldown 1% after pausing its $3B share buyback program